Perioperative Systemic Therapy in Rare, Chemosensitive Subtypes of Retroperitoneal Sarcoma: A Hospital-Based...

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Debate exists regarding the role of perioperative chemotherapy in retroperitoneal sarcoma (RPS).
• Focus on chemosensitive subtypes: angiosarcoma, undifferentiated pleomorphic sarcoma, myxoid liposarcoma, spindle cell sarcoma, and synovial sarcoma.

Purpose of the Study:

• To evaluate the effectiveness of perioperative chemotherapy in specific chemosensitive subtypes of RPS.
• To identify factors influencing chemotherapy use and their impact on survival in localized RPS.

Main Methods:

• Population-based retrospective cohort study using the US National Cancer Database (NCDB).
• Included 851 patients with localized RPS who underwent surgery (2004-2020).
• Propensity score matching and multivariable regression analyses were employed.

Main Results:

• 26.7% of patients received perioperative chemotherapy.
• Age ≤ 60 and higher tumor grade (GIII/IV) were associated with increased chemotherapy use.
• No significant difference in overall survival was observed between chemotherapy and non-chemotherapy groups post-matching (HR 0.89, p=0.92).

Conclusions:

• Perioperative chemotherapy was not associated with improved survival in chemosensitive RPS subtypes.
• Patient age and tumor grade influenced survival outcomes.
• Selection bias is a critical consideration for interpreting these findings.